
Pavmed (($PAVM)) has held its Q3 earnings call. Read on for the main highlights of the call. PAVmed’s earnings call carried a predominantly positive tone as Lucid reached nationwide Medicare
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PAVM | PAVmed | 1.32 | -8.82 | -86.98% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.32 | -86.98% |

Pavmed (($PAVM)) has held its Q3 earnings call. Read on for the main highlights of the call. PAVmed’s earnings call carried a predominantly positive tone as Lucid reached nationwide Medicare

PAVmed ( ($PAVM) ) has issued an announcement. On November 13, 2026, PAVmed reported that Lucid Diagnostics had begun receiving Medicare payments in October for EsoGuard tests, which were fully

Reports preliminary Q3 revenue $41,000 vs. $5,000 last year. PAVmed (PAVM) had cash and cash equivalents of $8.9M, including restricted cash of $5.3M, as of September 30, compared to cash

Pavmed (PAVM) is scheduled to report 3rd quarter earnings on 11/13/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Pavmed to post earnings of -$0.59 per share.

PAVmed ( ($PAVM) ) has shared an announcement. On October 21, 2026, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., closed a $15 million private financing by selling 15,000 shares

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has begun receiving payments from Medicare for its EsoGuard Esophageal DNA Test. The company also closed a $15M private

PAVmed ( ($PAVM) ) has provided an update. On September 9, 2026, PAVmed Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners to conduct an at‑the‑market offering of up

Ascendiant analyst Edward Woo raised the firm’s price target on PAVmed (PAVM) to $57 from $56 and keeps a Buy rating on the shares. The firm views the company’s Q2

Pavmed (($PAVM)) has held its Q2 earnings call. Read on for the main highlights of the call. PAVmed’s latest earnings call mixed solid operational progress with stark funding concerns. Executives

Reports Q2 revenue $33,000 vs. $6,000 last year. “PAVmed (PAVM) saw tangible progress across its core businesses during this past quarter and recent weeks,” said Lishan Aklog, M.D., PAVmed’s Chairman
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 30, 2027TBA | $12.07M | $-0.42 | $125.00K | 0.01 | -0.16 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.